Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's CEO, Brian Lian, Ph.D., will deliver a corporate presentation on Monday, January 13, 2025, from 1:30 to 2:10 p.m. Pacific time at The Westin St. Francis San Francisco on Union Square.

The presentation will be accessible via live webcast through the Viking Therapeutics website's Investors & Media section under Webcasts. A replay will be available on the company's website after the conference. Dr. Lian will also participate in one-on-one meetings during the event.

Viking Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for metabolic and endocrine disorders.

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 43^rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California.

Details are as follows:

• 43^rd Annual J.P. Morgan Healthcare Conference
  Details: Dr. Lian will deliver a corporate presentation and participate in 1-on-1 meetings
  Conference dates: January 13-16, 2025
  Presentation Timing: 1:30 – 2:10 p.m. Pacific on Monday, January 13, 2025
  Location: The Westin St. Francis San Francisco on Union Square; webcast available

A live webcast of the presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.  Additionally, a replay of the webcast will be available on the Viking website following the conference. 

About Viking Therapeutics, Inc. 

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.  The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.  In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302340335.html

SOURCE Viking Therapeutics, Inc.

FAQ

When is Viking Therapeutics (VKTX) presenting at the J.P. Morgan Healthcare Conference 2025?

Viking Therapeutics is presenting on Monday, January 13, 2025, from 1:30 to 2:10 p.m. Pacific time.

How can investors watch Viking Therapeutics' (VKTX) J.P. Morgan Conference presentation?

Investors can watch the presentation via live webcast through Viking Therapeutics' website in the Investors & Media section under Webcasts. A replay will be available after the conference.

What is the focus of Viking Therapeutics' (VKTX) research and development?

Viking Therapeutics focuses on developing novel therapies for metabolic and endocrine disorders.

Where will the Viking Therapeutics (VKTX) J.P. Morgan Healthcare Conference presentation take place?

The presentation will take place at The Westin St. Francis San Francisco on Union Square.

Will Viking Therapeutics (VKTX) be conducting individual meetings at the J.P. Morgan Healthcare Conference?

Yes, CEO Brian Lian will participate in one-on-one meetings during the conference.